Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC Matured DC vs Montanide Adjuvant for Melanoma Peptide Vaccination
NCT02334735Phase 2Completed
- Sponsor
- Nina Bhardwaj
- Start
- Jul 2015
- Primary completion
- Jul 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NY-ESO-1 peptide-pulsed dendritic cells + Melan-A/MART-1 peptide-pulsed dendritic cells in melanoma, sponsored by Nina Bhardwaj. Started Jul 2015; status: completed.
02
Drugs
NY-ESO-1 peptide-pulsed dendritic cells + Melan-A/MART-1 peptide-pulsed dendritic cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02334735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334735.